New obesity drug HM17321 enters first human safety trials

NCT ID NCT07219589

Recruiting now Disease control Sponsor: Hanmi Pharmaceutical Company Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new drug, HM17321, to see if it is safe and how the body processes it. About 90 healthy and obese adults will receive either the drug or a placebo as a shot under the skin. The main goal is to check for side effects, not to treat obesity yet.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HM17321
What this could lead to: If successful, this could lead to a new injectable medication for weight management in people with obesity.
What could go wrong: This is a very early Phase 1 study focused on safety, not weight loss. The drug may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESE OBESITY

Contacts and locations

Locations

Medpace Clinical Pharmacology Unit
RECRUITING

Cincinnati, Ohio, 45227, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.